8 results about "Cosmeceutical" patented technology

This invention relates to a Torreya grandis seed polypeptide with antioxidant and hyaluronidase inhibitory activities, its preparation, and its application. The method includes the following steps: S1, mixing Torreya grandis seed powder and ethanol for defatting to obtain a solid phase; S2, preparing the solid phase into a solution, acidifying it, then enzymatically hydrolyzing it with pepsin, inactivating the enzyme, centrifuging to collect the liquid phase, and freeze-drying it to obtain Torreya grandis seed polypeptide powder. Compared with the prior art, this invention provides a simple, reasonable, and efficient preparation method for Torreya grandis seed polypeptide, exhibiting good activity. It also proposes the application of Torreya grandis seed polypeptide in antioxidant and hyaluronidase activity inhibition, expanding its application in the fields of cosmeceuticals and food.

The invention relates to a method of preparing a microneedle array, comprising the steps of dissolving a water-soluble copolymer, comprising maleic anhydride and isobutylene monomers, in an aqueous solvent to obtain an aqueous solution, adding a ceramic material to said aqueous solution to obtain an aqueous ceramic slurry for gel casting, adding at least a portion of said aqueous ceramic slurry to a mould to obtain a layer of aqueous ceramic slurry in said mould, degassing said layer of aqueous ceramic slurry to obtain a degassed layer of aqueous ceramic slurry in said mould, gelling said degassed layer of aqueous ceramic slurry to remove said aqueous solvent from said aqueous ceramic slurry and removing said mould to obtain a gelled tape, drying said gelled tape to obtain a green tape, sintering said green tape to obtain said microneedle array. Further, the invention provides for a green tape, comprising a base plate and a set of microneedles integrated with said base plate, a microneedle array, comprising a base plate and a set of microneedles integrated with said base plate, a system for enabling transport of a substance through a material barrier, and a use of a microneedle array for intradermal drug or vaccine delivery, diagnostics, cosmeceuticals,, sensing of biomarkers found in the skin and monitoring of physiological conditions of the body.

The invention relates to the technical field of cosmeceuticals, in particular to a tightening essence spray. The anti-wrinkle mask is prepared from the following components in percentage by mass: 83.56% of bifidus yeast fermentation product filtrate, 6.5% of an anti-wrinkle agent A, 3.5% of an anti-wrinkle agent B, 2.5% of a preservative, 1.5% of nicotinamide, 1% of an anti-wrinkle agent C, 1% of Wailing enzyme, 0.11% of dipotassium glycyrrhizinate, 0.11% of allantoin, 0.11% of fullerene and 0.11% of hydrolyzed collagen. The anti-wrinkle agent A contains arginine / lysine polypeptide, and the molecular weight of the anti-wrinkle agent A is 1t; the 500Da oligopeptide chain can directly penetrate through the stratum corneum, and is competitively combined with the SNAP-25 protein to block the transmission of neuromuscular signals. The anti-wrinkle agent B contains acetyl hexapeptide-8, and forms a'nerve blocking-muscle relaxing 'closed loop with the anti-wrinkle agent A by inhibiting a calcium ion channel and reducing the depth of dynamic lines, and the effect is remarkable. The nicotinamide in the invention blocks melanosome transfer, activates an AMPK pathway to promote autophagy flow, and accelerates the degradation of generated melanin. The dipotassium glycyrrhizinate inhibits COX-2 inflammatory enzyme, reduces the level of PGE2 inflammatory factors induced by ultraviolet rays, and blocks inflammatory chromaticity.

The present invention relates to heparan sulfate sugar mimetic compounds as heparan sulfate mimetics, and the use of these compounds as medicaments, cosmeceuticals and as molecular probes. The invention also relates to intermediate compounds useful in the preparation of various sugar mimetic compounds. The invention is particularly suitable for treating or preventing diseases such as cancer, inflammation, diabetic nephropathy, neurodegenerative diseases, for bone healing or wound healing, for cosmeceutical use, and as molecular probes comprising imaging agents.

The disclosure provides embodiments directed to a 1,3-butylene glycol (BG) product that has a neutral odor, a composition comprising the BG product described here, and methods of using the BG product and compositions comprising the BG products. BG products described here demonstrate exemplary qualities and characteristics of being natural, sustainable, and having a neutral odor for use in cosmetics, cosmeceuticals, and personal care products. Such BG compositions of the description provide a BG product that does not mask or alter the fragrance notes of the cosmetics, cosmeceuticals, and personal care products. The BG products and compositions comprising such BG products as disclosed here are cost-effective while maintaining a neutral odor.

The claimed solution relates to pharmaceuticals, cosmeceuticals, medicine and veterinary medicine and can be used for producing an effective and safe analgesic for the treatment of pain of different origins, thereby providing relief for acute and chronic pain. The solution is directed toward the development of radically new analgesics of endogenous origin capable of rivaling opiates and opioids in a variety of indices. The essence of the solution consists in a technology for the creation of an analgesic substance that is a chelate complex of general formula CTS-M2+, where CTS is a molecule of a cardiotonic steroid, and М2+ is any doubly charged inorganic cation. In a specific embodiment, the substance is a calcium chelate complex of a molecule of ouabain. Proposed are methods for administering a pharmaceutical composition based on the claimed analgesic substance, which is provided in an injectable form or in the form of a cream, ointment, gel or the like.

A composition of rhPDGF-BB for the regeneration, rejuvenation, strengthening, comfort or aesthetic usefulness of soft tissue in the field of cosmetics and cosmeceuticals, comprising rhPDGF-BB combined with a carrier selected from the group consisting of different types of collagen, gelatin, alginates, polysaccharides, glycosaminoglycans, fibrin, hyaluronic acid and derivatives or combinations thereof, wherein damage to skin or soft tissue is treated by application of the disclosed composition.

A computerized system for initiating preparation of a customized cosmeceutical formulation, comprising a processor configured to execute program instructions to instantiate a cosmeceutical utility configured for (i) obtaining a skin type, a first skin concern and a prioritized set of second skin concerns from a user; (ii) selecting a base composition from a set of base compositions based on the skin type and the first skin concern; (iii) selecting a subset of booster compositions by determining a prioritized original set of booster compositions based on the prioritized set of second skin concerns; and verifying mutual compatibility of a subset of booster compositions in the original set. If the verifying indicates incompatibility among two or more booster compositions in the subset, the utility is configured to substitute a lower-priority booster composition in the two or more booster compositions with a booster composition that is in the original set but not in the subset; and (iv) causing an electronic message comprising a request to be released towards a recipient, the request identifying the selected base composition and the selected subset of booster compositions.